Safety and efficiency evaluation of the combined therapy of 89Sr plus zoledronic acid in patients with painful bone metastases
10.3969/j.issn.1000-8179.2015.23.113
- VernacularTitle:89Sr联合唑来膦酸治疗骨转移瘤骨痛的安全性及疗效评价
- Author:
Qingju ZHANG
;
Wengui XU
;
Dong DAI
;
Xiuyu SONG
- Publication Type:Journal Article
- Keywords:
89Sr;
zoledronic acid;
bone metastases;
combined therapy
- From:
Chinese Journal of Clinical Oncology
2015;(23):1138-1142
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate and compare the safety and efficiency of the combined therapy of 89Sr plus zoledronic acid and those of 89Sr-chloride alone, in patients with painful bone metastases. Methods: A total of 87 patients with osseous metastasis were ran-domly divided into treatment groups of 89Sr-chloride alone (group A, 53 patients) and 89Sr plus zoledronic acid (group B, 34 patients). A total of 17 patients in group B received zoledronic acid 2-14 days after 89Sr therapy, and 13 other patients in the group received 89Sr 4-7 days after zoledronic-acid therapy. Pain response and KPS score were evaluated after the different treatments. Results: No obvious bone marrow suppression and liver damage were found in all cases. All patients who received both 89Sr-chloride and 89Sr plus zoledronic acid showed reduced bone pain and total discomfort, as well as improved KPS score, but the response was more pronounced in group B (P=0.047; P=0.036). No statistical differences in pain score and KPS scores were observed between the groups treated with zoledronic acid first and 89Sr therapy first (P=1.000; P=0.667). Comparison of bone pain relief and changes in the KPS score of different primary tumors after treatment with 89Sr-chloride or 89Sr plus zoledronic acid showed no statistical significance. Conclusion: Compared with 89Sr-chloride, treatment with 89Sr plus zoledronic acid was more effective in patients with painful bone metastases. The safety of these two treatments are similar.
